Lambert Eaton Myasthenic Syndrome Lems Market

DelveInsight's "Lambert-Eaton Myasthenic Syndrome (LEMS) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Lambert-Eaton Myasthenic Syndrome (LEMS), historical and forecasted epidemiology as well as the Lambert-Eaton Myasthenic Syndrome (LEMS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Lambert-Eaton Myasthenic Syndrome (LEMS) market report provides current treatment practices, emerging drugs, Lambert-Eaton Myasthenic Syndrome (LEMS) market share of the individual therapies, current and forecasted Lambert-Eaton Myasthenic Syndrome (LEMS) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Lambert-Eaton Myasthenic Syndrome (LEMS) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.


Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Study Period: 2017-2030


Lambert-Eaton Myasthenic Syndrome (LEMS) Disease Understanding and Treatment Algorithm

Lambert–Eaton myasthenic syndrome (LEMS) is an autoimmune disease in which the immune system attacks the body's own tissues. The attack occurs at the connection between nerve and muscle (the neuromuscular junction) and interferes with the ability of nerve cells to send signals to muscle cells. Specifically, the immune system attacks the calcium channels on nerve endings that are required to trigger the release of chemicals (acetylcholine). With fewer calcium channels, the nerve ending releases less acetylcholine. Acetylcholine is a chemical messenger that triggers muscle contraction. In people with LEMS, the lowered levels of acetylcholine are not sufficient to cause normal muscle contractions, causing muscle weakness. The disease is named for Edward Lambert and Lee Eaton, neurologists at the Mayo Clinic in Rochester, Minn., who first described the myasthenic syndrome in the 1950s and 1960s.


There are two types of LEMS, paraneoplastic, in which the disease is associated with cancer and non-paraneoplastic with no known underlying cause.


Diagnosis 

The presence of clinical features such as proximal muscle weakness associated with areflexia and autonomic dysfunction should prompt an evaluation for LEMS. The diagnosis of LEMS is often difficult if the disease is not suspected since weakness in the legs with or without arm weakness and fatigue are common complaints in general. The diagnosis is more likely to be suspected in people with cancer. Often, the initial suspected diagnosis is myasthenia gravis (MG), due to an overlap in symptoms. The presence of a dry mouth is also a helpful clue. The diagnosis of LEMS can be confirmed by the presence of antibodies against P/Q-type voltage-gated calcium channels (VGCC) along with electrodiagnostic studies.


If a diagnosis of LEMS is confirmed, a CT scan of the is obtained to look for a small cell lung cancer. If negative, a PET-CT is considered. If negative, follow-up chest CTs are recommended for up to 5 years to monitor for underlying cancer. A 2010 taskforce recommended repeating this screening at three to six months, and then every six months for two years in people with LEMS, if testing remains unrevealing. Most cancers, if present, are detected in the first year.

Continued in the report…..


Treatment 

There is no cure for LEMS, as scientists have not yet figured out how to selectively stop the autoimmune attack on motor nerve terminal calcium channels and other nerve terminal proteins targeted by LEMS. Therefore, symptomatic treatments for neuromuscular weakness that results from LEMS are favored. Medications and therapies that may be used to treat LEMS include 3, 4-diaminopyridine (enhances acetylcholine release), anticholinesterase agents (e.g., pyridostigmine), plasma exchange, intravenous immunoglobulins (IVIG), and medications that suppress the immune system (e.g., prednisone, azathioprine).

Lambert-Eaton Myasthenic Syndrome (LEMS) Epidemiology  

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of LEMS, Total Diagnosed Prevalent Cases of LEMS, Gender-specific Diagnosed Prevalent Cases of LEMS, Type-specific Diagnosed Prevalent Cases of LEMS, and Diagnosed Prevalent Cases of LEMS by Malignancy scenario of LEMS in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.


Key Findings

  • Total prevalent cases of LEMS in the 7MM was found to be 5,977 in 2017.
  • Based on the etiology, LEMS is divided into two types; paraneoplastic and idiopathic. There were a total 1,978 diagnosed prevalent cases of LEMS in the United States in 2017, out of which 1,154 accounted for paraneoplastic and 824 cases accounted for idiopathic.
  • As per the assessments, in the 7MM, the majority of cases of LEMS are paraneoplastic form as compared to idiopathic form.
  • Among the two forms of LEMS, the paraneoplastic form constitutes more than half of the cases and is mostly associated with intrathoracic neoplasms. Most of the cases were seen with small cell lung cancer (SCLC); other subtypes of lung cancer are extremely rare.
  • Among the EU-5 countries, Germany witnessed the highest prevalent population accounting for 6.93% of the total prevalent cases in 7MM, followed by France and the United Kingdom. On the other hand, Spain witnessed the lowest number of prevalent cases in 2017.
  • Japan was assessed with 21.32% of the total prevalent population, with 1,274 cases observed in 2017.


Country Wise- Lambert-Eaton Myasthenic Syndrome (LEMS) Epidemiology 

The epidemiology segment also provides the Lambert-Eaton Myasthenic Syndrome (LEMS) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. 


Lambert-Eaton Myasthenic Syndrome (LEMS) Drug Chapters

Drug chapter segment of the Lambert-Eaton Myasthenic Syndrome (LEMS) report encloses the detailed analysis of Lambert-Eaton Myasthenic Syndrome (LEMS) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Lambert-Eaton Myasthenic Syndrome (LEMS) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.


Marketed Drugs 


Firdapse: Catalyst Pharmaceutical

Firdapse (amifampridine) is a potassium channel blocker used to treat LEMS in adults. The active ingredient of Firdapse is amifampridine phosphate, which is a voltage-gated potassium channel blocker. Amifampridine phosphate is described chemically as 3, 4-diaminopyridine phosphate. Each Firdapse tablet contains 10 mg amifampridine (equivalent to 18.98 mg amifampridine phosphate). The drug was developed by BioMarin Pharmaceutical and is marketed by Catalyst Pharmaceutical, which secured the marketing rights to Firdapse in North America.


In June 2019, Catalyst Pharmaceutical filed a lawsuit against the US FDA over the regulatory agency’s decision to approve a rival treatment for its newly-approved LEMS. Documents released in court, including partially redacted emails from the FDA, appear to show that issues regarding the list price for Firdapse (amifampridine). The lawsuit alleges that the approval of Ruzurgi, a rival drug from privately held Jacobus Pharmaceutical Co, in May 2019, violated provisions of FDA regulations and Catalyst’s rights to exclusivity for its drug, Firdapse.


Catalyst recently announced plans to expand sales to Japan. They recently had talks with the Japanese Ministry of Health, Labor and Social Affairs (MHLW) to get Firdapse approved in Japan.

Products detail in the report…


Ruzurgi: Jacobus Pharmaceutical Company Inc.

Ruzurgi (amifampridine) is a potassium channel blocker indicated for the treatment of LEMS in patients 6 years to less than 17 years of age. It is supplied as a tablet for oral administration. Ruzurgi is designed to prolong signals that are released from nerves to allow greater stimulation of the muscle. Ruzurgi works in a similar mechanism to Firdapse (amifampridine phosphate), which was approved in 2018 for the treatment of adults with LEMS. The drug was initially developed as a phosphate salt of amifampridine by Assistance Publique Hôpitaux de Paris. It was later developed and commercialized by various companies, including BioMarin Pharmaceutical, Catalyst Pharmaceuticals, and Jacobus Pharmaceutical.

Products detail in the report…


Lambert-Eaton Myasthenic Syndrome (LEMS) Emerging Drugs 

The report provides the details of the emerging therapies under the late and mid-stage of development for Lambert-Eaton Myasthenic Syndrome (LEMS) treatment. 


Lambert-Eaton Myasthenic Syndrome (LEMS) Market Outlook

The therapeutic market of LEMS in the seven major markets was assessed to be USD 59.43 million in 2017 (With Base Case Scenario* and Downside Scenario**) and is expected to grow during the study period (2017–2030).


Currently, there is no cure for LEMS and treatment is mainly symptomatic. This includes 3, 4-diaminopyridine phosphate (DAP), which is usually well-tolerated and effective. In some patients, the combination of pyridostigmine with 3, 4-DAP has been suggested to have an additional positive effect. If symptomatic treatment is insufficient, immunosuppressive therapy with prednisone, alone or in combination with azathioprine, can achieve long-term control of the disorder. Plasmapheresis and high dose administration of intravenous immunoglobulins (IVIGs) have a short effect. An effective treatment against any tumor present is mandatory, both to control the tumor and to improve the clinical symptoms of LEMS.


So far, there are only two FDA approved the medication for LEMS, i.e., Firdapse and Ruzurgi. The FDA’s approval of Firdapse is a potentially transformative milestone in the lives of patients in the US suffering from LEMS, as it now gives adult LEMS patients access to a new first-in-class-therapy. Firdapse is approved in the US and the European Union for use by patients with LEMS.


After the approval of Firdapse, Ruzurgi is the second drug to be approved in the US for the treatment of LEMS and first approved the medication for the treatment of LEMS in patients 6 years to less than 17 years of age. Despite being a potential therapy in the treatment, a lawsuit has been filed by Catalyst Pharma against the US FDA and several related parties challenging the recent approval of an NDA and related drug labeling for Ruzurgi for the treatment of LEMS in pediatric patients. The lawsuit alleges that the approval of Ruzurgi, Catalyst’s rival medicine from privately held Jacobus Pharmaceutical, in May violated provisions of US FDA’s regulations and Catalyst’s rights to exclusivity for its drug, Firdapse. Both drugs are approved to treat LEMS, but Firdapse was approved for adults, while Jacobus’ drug was for children.


Presently there are no approved therapies of LEMS in Japan, Catalyst Pharma announced the plan to expand sales of Firdapse in Japan. They recently had talks with the Japanese Ministry of Health, Labor and Social Affairs (MHLW) to get Firdapse approved in Japan. About two years ago, the Japanese government approved Firdapse as a primary drug for the MHLW and actively asked companies to develop and submit an NDA for the drug. Once Catalyst and MHLW have reached agreement on what will be required to file this NDA in Japan, an update of the approval process for filing an NDA in Japan will be released.


According to DelveInsight, the market size of LEMS in the seven major market (7MM) is expected to change during the study period 2017–2030.


*Base Case Scenario: With the Base Case Scenario, DelveInsight’s analysts estimate that Ruzurgi will not be launch in the market because Catalyst has filed a suit against Jacobus’ drug (Ruzurgi). Therefore, it is estimated that Firdapse will cover a decent market in the upcoming years without any competition


**Downside Scenario: With Downside Scenario, DelveInsight is expecting the launch of Ruzurgi in the United States in the second half of 2020, which will compete and likely to take the market share of Firdapse.


Key Findings

This section includes a glimpse of the Lambert-Eaton Myasthenic Syndrome (LEMS) market in 7MM.

  • In 2017, the market size of LEMS in the 7MM was USD 59.43 million.
  • Among the 7MM, the United States accounted for the majority of the market size with USD 32.85 million in 2017.
  • The current market size of LEMS is entirely dependent on symptomatic treatment regimens, includes Firdapse, 3, 4-diaminopyridine (base), pyridostigmine, immunoglobulin, and others). Others include guanidine, acetylcholinesterase (AChE) inhibitors, prednisone, azathioprine, cyclosporine, and plasmapheresis.
  • Firdapse (Catalyst Pharmaceuticals) is the only approved therapy for the treatment of LEMS in adults in the United States and EU5.
  • Another Molecule Ruzurgi (Jacobus Pharmaceuticals), is approved by the US FDA in May 2019, for the treatment of patients with LEMS age six to less than 17 years. However, In June 2019, Catalyst filed its lawsuit in the US District Court for the Southern District of Florida and is seeking a reversal of FDA's decision.
  • DelveInsight estimates that Japan has the second-highest market size after the United States in 2017, which is accounted for USD 9.59 million.


The United States Market Outlook

This section provides the total Lambert-Eaton Myasthenic Syndrome (LEMS) market size and market size by therapies in the United States.


EU-5 Countries: Market Outlook

The total Lambert-Eaton Myasthenic Syndrome (LEMS) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.


Japan Market Outlook 

The total Lambert-Eaton Myasthenic Syndrome (LEMS) market size and market size by therapies in Japan is also mentioned. 


Lambert-Eaton Myasthenic Syndrome (LEMS) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Lambert-Eaton Myasthenic Syndrome (LEMS) market or expected to get launched in the market during the study period 2017-2030. The analysis covers Lambert-Eaton Myasthenic Syndrome (LEMS) market uptake by drugs; patient uptake by therapies; and sales of each drug.    

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


Lambert-Eaton Myasthenic Syndrome (LEMS) Pipeline Development Activities 

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Lambert-Eaton Myasthenic Syndrome (LEMS) key players involved in developing targeted therapeutics. 


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Lambert-Eaton Myasthenic Syndrome (LEMS) emerging therapies.


Reimbursement Scenario in Lambert-Eaton Myasthenic Syndrome (LEMS)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy. 


KOL- Views 

To keep up with current market trends, we take KOLs and SME's opinion working in Lambert-Eaton Myasthenic Syndrome (LEMS) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Lambert-Eaton Myasthenic Syndrome (LEMS) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs. 


Competitive Intelligence Analysis 

We perform Competitive and Market Intelligence analysis of the Lambert-Eaton Myasthenic Syndrome (LEMS) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.


Scope of the Report

  • The report covers the descriptive overview of Lambert-Eaton Myasthenic Syndrome (LEMS), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Lambert-Eaton Myasthenic Syndrome (LEMS) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Lambert-Eaton Myasthenic Syndrome (LEMS) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Lambert-Eaton Myasthenic Syndrome (LEMS) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Lambert-Eaton Myasthenic Syndrome (LEMS) market


Report Highlights

  • In the coming years, Lambert-Eaton Myasthenic Syndrome (LEMS) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Lambert-Eaton Myasthenic Syndrome (LEMS) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition       
  • Major players are involved in developing therapies for Lambert-Eaton Myasthenic Syndrome (LEMS). Launch of emerging therapies will significantly impact the Lambert-Eaton Myasthenic Syndrome (LEMS) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Lambert-Eaton Myasthenic Syndrome (LEMS)
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities


Lambert-Eaton Myasthenic Syndrome (LEMS) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Lambert-Eaton Myasthenic Syndrome (LEMS) Pipeline Analysis
  • Lambert-Eaton Myasthenic Syndrome (LEMS) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies


Lambert-Eaton Myasthenic Syndrome (LEMS) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage 
  • Lambert-Eaton Myasthenic Syndrome (LEMS) Epidemiology Segmentation
  • Key Cross Competition 
  • Highly Analyzed Market
  • Drugs Uptake


Lambert-Eaton Myasthenic Syndrome (LEMS) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers


Key Questions

Market Insights:

  • What was the Lambert-Eaton Myasthenic Syndrome (LEMS) market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Lambert-Eaton Myasthenic Syndrome (LEMS) total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Lambert-Eaton Myasthenic Syndrome (LEMS) market size during the forecast period (2017-2030)?
  • At what CAGR, the Lambert-Eaton Myasthenic Syndrome (LEMS) market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Lambert-Eaton Myasthenic Syndrome (LEMS) market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Lambert-Eaton Myasthenic Syndrome (LEMS) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Lambert-Eaton Myasthenic Syndrome (LEMS)?
  • What is the historical Lambert-Eaton Myasthenic Syndrome (LEMS) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Lambert-Eaton Myasthenic Syndrome (LEMS) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Lambert-Eaton Myasthenic Syndrome (LEMS)?
  • Out of all 7MM countries, which country would have the highest prevalent population of Lambert-Eaton Myasthenic Syndrome (LEMS) during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Lambert-Eaton Myasthenic Syndrome (LEMS) treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) in the USA, Europe, and Japan?
  • What are the Lambert-Eaton Myasthenic Syndrome (LEMS) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS)?
  • How many therapies are developed by each company for Lambert-Eaton Myasthenic Syndrome (LEMS) treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Lambert-Eaton Myasthenic Syndrome (LEMS) treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Lambert-Eaton Myasthenic Syndrome (LEMS) therapies? 
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies? 
  • What are the clinical studies going on for Lambert-Eaton Myasthenic Syndrome (LEMS) and their status?
  • What are the key designations that have been granted for the emerging therapies for Lambert-Eaton Myasthenic Syndrome (LEMS)?
  • What are the global historical and forecasted market of Lambert-Eaton Myasthenic Syndrome (LEMS)?


Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Lambert-Eaton Myasthenic Syndrome (LEMS) market
  • To understand the future market competition in the Lambert-Eaton Myasthenic Syndrome (LEMS) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Lambert-Eaton Myasthenic Syndrome (LEMS) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Lambert-Eaton Myasthenic Syndrome (LEMS) market
  • To understand the future market competition in the Lambert-Eaton Myasthenic Syndrome (LEMS) market

"

1. Key Insights

2. Executive Summary

3. Lambert–Eaton Myasthenic Syndrome (LEMS): Market Overview at a Glance (Base Case Scenario)

3.1. Market Share (%) Distribution of LEMS in 2017

3.2. Market Share (%) Distribution of LEMS in 2030

4. Lambert–Eaton Myasthenic Syndrome (LEMS): Market Overview at a Glance (Downside Scenario)

4.1. Market Share (%) Distribution of LEMS in 2017

4.2. Market Share (%) Distribution of LEMS in 2030

5. Lambert–Eaton Myasthenic Syndrome (LEMS): Disease Overview

5.1. Introduction

5.2. Signs and Symptoms

5.3. Cause of Lambert–Eaton Myasthenic Syndrome

5.4. Risk Factors

5.5. Pathophysiology Lambert–Eaton Myasthenic Syndrome

5.6. Pathogenesis

5.7. Clinical Manifestations

5.8. Diagnosis

5.9. Diagnostic Algorithm

6. Case Reports

6.1. Lambert–Eaton Myasthenic Syndrome Associated with Atypical Bronchopulmonary Carcinoid Tumor

6.2. A Case of Lambert–Eaton Myasthenic Syndrome Associated with Atypical Bronchopulmonary Carcinoid Tumor

7. Epidemiology and Patient Population

7.1. Epidemiology Methodology

7.2. Key Findings

7.3. Total Prevalent Cases of Lambert–Eaton Myasthenic Syndrome (LEMS) in the 7MM

7.4. Total Diagnosed Prevalent Cases of Lambert–Eaton Myasthenic Syndrome (LEMS) in the 7MM

8. United States Epidemiology

8.1. Assumptions and Rationale

8.2. Total Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in the United States

8.3. Total Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in the United States

8.4. Gender-specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in the United States

8.5. Type-specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in the United States

8.6. Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) by Malignancy in the United States

9. EU-5 Epidemiology

9.1. Germany

9.1.1. Total Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Germany

9.1.2. Total Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Germany

9.1.3. Gender-specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Germany

9.1.4. Type-specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Germany

9.1.5. Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) by Malignancy in Germany

9.2. France

9.2.1. Total Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in France

9.2.2. Total Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in France

9.2.3. Gender-specific Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in France

9.2.4. Type-specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in France

9.2.5. Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) by Malignancy in France

9.3. Italy

9.3.1. Total Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Italy

9.3.2. Total Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Italy

9.3.3. Gender-specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Italy

9.3.4. Type-specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Italy

9.3.5. Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) by Malignancy in Italy

9.4. Spain

9.4.1. Total Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Spain

9.4.2. Total Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Spain

9.4.3. Gender-specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Spain

9.4.4. Type-specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Spain

9.4.5. Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) by Malignancy in Spain

9.5. United Kingdom

9.5.1. Total Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in the United Kingdom

9.5.2. Total Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in the United Kingdom

9.5.3. Gender-specific Diagnosed Prevalent Cases of LEMS in the United Kingdom

9.5.4. Type-specific Diagnosed Prevalent Cases of LEMS in the United Kingdom

9.5.5. Diagnosed Prevalent Cases of LEMS by Malignancy in the United Kingdom

10. Japan Epidemiology

10.1. Assumptions and Rationale

10.2. Total Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Japan

10.3. Total Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Japan

10.4. Gender-specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Japan

10.5. Type-specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Japan

10.6. Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) by Malignancy in Japan

11. Treatment

11.1. Treatment Guidelines

11.1.1. Italian recommendations for Lambert–Eaton myasthenic syndrome (LEMS) management

11.1.2. EFNS Guidelines: Guidelines for treatment of autoimmune neuromuscular transmission disorders

12. Unmet Needs

13. Marketed Drugs

13.1. Firdapse: Catalyst Pharmaceutical

13.1.1. Product Description

13.1.2. Other Developmental Activities

13.1.3. Clinical Development

13.1.4. Clinical Trials Information

13.1.5. Safety and Efficacy

13.1.6. Product Profile

13.2. Ruzurgi: Jacobus Pharmaceutical Company Inc.

13.2.1. Product Description

13.2.2. Other Developmental Activities

13.2.3. Clinical Development

13.2.4. Clinical Trials Information

13.2.5. Safety and Efficacy

13.2.6. Product Profile

14. Lambert–Eaton Myasthenic Syndrome (LEMS): 7MM Market Analysis

14.1. Market Methodology

14.2. Key Findings

14.3. Market Size of Lambert–Eaton Myasthenic Syndrome (LEMS) in 7MM (With Base Case Scenario)

14.4. Market Size of LEMS by Therapies in the 7MM (With Base Case Scenario)

14.5. Market Size of Lambert–Eaton Myasthenic Syndrome (LEMS) in the 7MM (With Downside Scenario)

14.6. Market Size of LEMS by Therapies in the 7MM (With Downside Scenario)

15. Market Outlook: The United States

15.1. United States Market Size

15.1.1. Total Market size of Lambert-Eaton Myasthenic Syndrome (LEMS) (With Base Case Scenario)

15.1.2. Lambert-Eaton Myasthenic Syndrome (LEMS) Market by Therapies (With Base Case Scenario)

15.1.3. Total Market size of Lambert-Eaton Myasthenic Syndrome (LEMS) (With Downside Scenario)

15.1.4. Lambert-Eaton Myasthenic Syndrome (LEMS) Market by Therapies (With Downside Scenario)

16. Market Outlook: Europe

16.1. Germany

16.1.1. Total Market size of Lambert–Eaton Myasthenic Syndrome (LEMS)

16.1.2. Lambert–Eaton Myasthenic Syndrome (LEMS) Market by Therapies

16.2. France

16.2.1. Total Market size of Lambert–Eaton Myasthenic Syndrome (LEMS)

16.2.2. Lambert–Eaton Myasthenic Syndrome (LEMS) Market by Therapies

16.3. Italy

16.3.1. Total Market size of Lambert–Eaton Myasthenic Syndrome (LEMS)

16.3.2. Lambert–Eaton Myasthenic Syndrome (LEMS) Market by Therapies

16.4. Spain

16.4.1. Total Market size of Lambert–Eaton Myasthenic Syndrome (LEMS)

16.4.2. Lambert–Eaton Myasthenic Syndrome (LEMS) Market by Therapies

16.5. United Kingdom

16.5.1. Total Market size of Lambert–Eaton Myasthenic Syndrome (LEMS)

16.5.2. Lambert–Eaton Myasthenic Syndrome (LEMS) Market by Therapies

17. Market Outlook: Japan

17.1. Total Market size of Lambert–Eaton Myasthenic Syndrome (LEMS)

17.2. Lambert–Eaton Myasthenic Syndrome (LEMS) Market by Therapies

18. Market Drivers

19. Market Barriers

20. SWOT Analysis

21. KOL Views

22. Reimbursement and market access

23. Appendix

23.1. Report Methodology

24. DelveInsight Capabilities

25. Disclaimer

26. About DelveInsight

Table 1 : 7MM Lambert-Eaton Myasthenic Syndrome (LEMS) Epidemiology (2017-2030)

Table 2 : 7MM Lambert-Eaton Myasthenic Syndrome (LEMS) Diagnosed and Treatable Cases (2017-2030)

Table 3 : Disease% Epidemiology in the United States (2017-2030)

Table 4 : Lambert-Eaton Myasthenic Syndrome (LEMS) Diagnosed and Treatable Cases in the United States (2017-2030)

Table 5 : Lambert-Eaton Myasthenic Syndrome (LEMS) Epidemiology in Germany (2017-2030)

Table 6 : Lambert-Eaton Myasthenic Syndrome (LEMS) Diagnosed and Treatable Cases in Germany (2017-2030)

Table 7 : Lambert-Eaton Myasthenic Syndrome (LEMS) Epidemiology in France (2017-2030)

Table 8 : Lambert-Eaton Myasthenic Syndrome (LEMS) Diagnosed and Treatable Cases in France (2017-2030) 

Table 9 : Lambert-Eaton Myasthenic Syndrome (LEMS) Epidemiology in Italy (2017-2030)

Table 10 : Lambert-Eaton Myasthenic Syndrome (LEMS) Diagnosed and Treatable Cases in Italy (2017-2030)

Table 11 : Lambert-Eaton Myasthenic Syndrome (LEMS) Epidemiology in Spain (2017-2030)

Table 12 : Lambert-Eaton Myasthenic Syndrome (LEMS) Diagnosed and Treatable Cases in Spain (2017-2030)

Table 13 : Lambert-Eaton Myasthenic Syndrome (LEMS) Epidemiology in the UK (2017-2030)

Table 14 : Lambert-Eaton Myasthenic Syndrome (LEMS) Diagnosed and Treatable Cases in the UK (2017-2030)

Table 15 : Lambert-Eaton Myasthenic Syndrome (LEMS) Epidemiology in Japan (2017-2030)

Table 16 : Lambert-Eaton Myasthenic Syndrome (LEMS) Diagnosed and Treatable Cases in Japan (2017-2030)

Table 17 : Drug Name, Clinical Trials by Recruitment status

Table 18 : Drug Name, Clinical Trials by Zone

Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)

Table 20 : Region-wise Market Size in USD, Million (2017-2030)

Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)

Table 22 : United States Market Size in USD, Million (2017-2030)

Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)

Table 24 : Germany Market Size in USD, Million (2017-2030)

Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)

Table 26 : France Market Size in USD, Million (2017-2030)

Table 27 : France Market Size by Therapy in USD, Million (2017-2030)

Table 28 : Italy Market Size in USD, Million (2017-2030)

Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)

Table 30 : Spain Market Size in USD, Million (2017-2030)

Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)

Table 32 : United Kingdom Market Size in USD, Million (2017-2030)

Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)

Table 34 : Japan Market Size in USD, Million (2017-2030)

Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

*The list of tables is not exhaustive; the final content may vary

Figure 1 : 7MM Lambert-Eaton Myasthenic Syndrome (LEMS) Epidemiology (2017-2030)

Figure 2 : 7MM Lambert-Eaton Myasthenic Syndrome (LEMS) Diagnosed and Treatable Cases (2017-2030)

Figure 3 : Lambert-Eaton Myasthenic Syndrome (LEMS) Epidemiology in the United States (2017-2030)

Figure 4 : Lambert-Eaton Myasthenic Syndrome (LEMS) Diagnosed and Treatable Cases in the United States (2017-2030)

Figure 5 : Lambert-Eaton Myasthenic Syndrome (LEMS) Epidemiology in Germany (2017-2030)

Figure 6 : Lambert-Eaton Myasthenic Syndrome (LEMS) Diagnosed and Treatable Cases in Germany (2017-2030)

Figure 7 : Lambert-Eaton Myasthenic Syndrome (LEMS) Epidemiology in France (2017-2030)

Figure 8 : Lambert-Eaton Myasthenic Syndrome (LEMS) Diagnosed and Treatable Cases in France (2017-2030) 

Figure 9 : Lambert-Eaton Myasthenic Syndrome (LEMS) Epidemiology in Italy (2017-2030)

Figure 10 : Lambert-Eaton Myasthenic Syndrome (LEMS) Diagnosed and Treatable Cases in Italy (2017-2030)

Figure 11 : Lambert-Eaton Myasthenic Syndrome (LEMS) Epidemiology in Spain (2017-2030)

Figure 12 : Lambert-Eaton Myasthenic Syndrome (LEMS) Diagnosed and Treatable Cases in Spain (2017-2030)

Figure 13 : Lambert-Eaton Myasthenic Syndrome (LEMS) Epidemiology in the UK (2017-2030)

Figure 14 : Lambert-Eaton Myasthenic Syndrome (LEMS) Diagnosed and Treatable Cases in the UK (2017-2030)

Figure 15 : Lambert-Eaton Myasthenic Syndrome (LEMS) Epidemiology in Japan (2017-2030)

Figure 16 : Lambert-Eaton Myasthenic Syndrome (LEMS) Diagnosed and Treatable Cases in Japan (2017-2030)

Figure 17 : Drug Name, Clinical Trials by Recruitment status

Figure 18 : Drug Name, Clinical Trials by Zone

Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)

Figure 20 : Region-wise Market Size in USD, Million (2017-2030)

Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)

Figure 22 : United States Market Size in USD, Million (2017-2030)

Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)

Figure 24 : Germany Market Size in USD, Million (2017-2030)

Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)

Figure 26 : France Market Size in USD, Million (2017-2030)

Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)

Figure 28 : Italy Market Size in USD, Million (2017-2030)

Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)

Figure 30 : Spain Market Size in USD, Million (2017-2030)

Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)

Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)

Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)

Figure 34 : Japan Market Size in USD, Million (2017-2030)

Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

*The list of figures is not exhaustive; the final content may vary.

  • Tags:
  • Lambert-Eaton Myasthenic Syndrome (...
  • Lambert-Eaton Myasthenic Syndrome (...
  • Lambert-Eaton Myasthenic Syndrome (...
  • Lambert-Eaton Myasthenic Syndrome (...
  • Lambert-Eaton Myasthenic Syndrome (...
  • Lambert-Eaton Myasthenic Syndrome (...
  • Lambert-Eaton Myasthenic Syndrome (...
  • Lambert-Eaton Myasthenic Syndrome (...
  • Lambert-Eaton Myasthenic Syndrome (...
  • Lambert-Eaton Myasthenic Syndrome (...
  • Lambert-Eaton Myasthenic Syndrome (...
  • Lambert-Eaton Myasthenic Syndrome (...
  • Lambert-Eaton Myasthenic Syndrome (...
  • Lambert-Eaton Myasthenic Syndrome (...

Forward to Friend

Need A Quote